Survival Benefits of Immune Checkpoint Inhibito...

By João L. Carapinha

March 21, 2025

A recent cohort study examined factors associated with immune checkpoint inhibitors (ICIs) treatment and outcomes in 18,932 metastatic colorectal cancer (mCRC) patients. Patients with microsatellite instability-high (MSI-H) tumors who received ear...

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.